Addiction
August 13, 2024
Beau Kilmer
3 citations
An increasing number of US states and localities are implementing or considering alternatives to prohibiting the supply and possession of some psychedelics for non-clinical use. Debates about these policy changes will probably differ from what we saw with cannabis. Andrews et al. correctly note that: 'The current push to broaden the production, sale, and use of psychedelics bears many parallels...
Addiction
August 12, 2024
Michael P. Bogenschutz
1 citation
Recent experience with off-label use of ketamine and recent challenges experienced in research with MDMA and psilocybin provide additional perspectives on how best to continue development of experimental psychedelic medications. Andrews et al. [1] provide a valuable perspective by noting the parallels between the ongoing deregulation of cannabis and what is now happening with psychedelics. The...
ACS Chemical Neuroscience
August 2, 2024
Fabio Urbina, Thane Jones, Joshua S. Harris et al.
9 citations
The development of new drugs addressing serious mental health and other disorders should avoid the psychedelic experience. Analogs of psychedelic drugs can have clinical utility and are termed “psychoplastogens”. These represent promising candidates for treating opioid use disorder to reduce drug dependence, with rarely reported serious adverse effects. This drug abuse cessation is linked to...
Annual Review of Psychology
August 2, 2024
Keith Humphreys, Daniel Stjepanović, Wayne Hall et al.
18 citations
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...
Psychopharmacology
August 1, 2024
Jacob S. Aday, David Horton, Gisele Fernandes-Osterhold et al.
39 citations
Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been...
Current Neurology and Neuroscience Reports
August 1, 2024
Daniel C Mograbi, Rafael S. Rodrigues, Bheatrix Bienemann et al.
12 citations
Self-awareness can be defined as the capacity of becoming the object of one's own awareness and, increasingly, it has been the target of scientific inquiry. Self-awareness has important clinical implications, and a better understanding of the neurochemical basis of self-awareness may help clarifying causes and developing interventions for different psychopathological conditions. The current...
Archive for the Psychology of Religion
July 26, 2024
Hemal P. Trivedi
2 citations
This article proposes a model of comparative mysticism that bases its rationale for comparison in the dynamic interaction between three components: neurocognitive mechanisms and substrates, phenomenal experiences, and noetic accounts. In examining the phenomenon of ego - dissolution ( EDn ), using this model, a scholar can identify universal and contextual components of a mystic’s experiences....
Journal of Psychedelic Studies
July 17, 2024
Liam Engel, Sascha Thal, Stephen Bright et al.
4 citations
Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing both harm reduction provisions and clinical research. This study extracts forum data on psychedelic substances, dosages, and administration routes, categorising and analysing self-reported consumption to inform care services and guide clinical work with...
Journal of Psychedelic Studies
July 12, 2024
Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart
1 citation
Abstract Background Previous international clinical trials have indicated that mystical experiences resulting from the consumption of classic psychedelic drugs, such as psilocybin, may represent a subjective psychological mechanism of action associated with therapeutic effects for various mental disorders. The revised 30-item Mystical Experience Questionnaire is one of several psychometric...
Current Psychology
July 12, 2024
William A. Schutt, Julie J. Exline, Kathleen C. Pait et al.
25 citations
Abstract Psychedelic substances, which can occasion mystical experiences, are sometimes used for religious and spiritual reasons. Despite strong links between psychedelics and spirituality, no previous systematic review has investigated connections between psychedelics and indicators of long-term spiritual growth. Thus, 34 empirical studies were analyzed with 19,724 total participants from 32...